Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

doi:10.20892/j.issn.2095-3941.2024.0503

. 2025 Apr 8;22(3):237-265.

doi: 10.20892/j.issn.2095-3941.2024.0503.

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Huijing Feng^#¹, Yang Xia^#², Wenxian Wang^#³, Chunwei Xu^#^{4

5}, Qian Wang^#⁶, Zhengbo Song³, Ziming Li⁷, Jinpu Yu⁸, Wenzhao Zhong⁹, Zhijie Wang¹⁰, Yongchang Zhang¹¹, Jingjing Liu¹², Shirong Zhang¹³, Xiuyu Cai¹⁴, Anwen Liu¹⁵, Wen Li², Ping Zhan⁵, Hongbing Liu⁵, Tangfeng Lyu⁵, Liyun Miao¹⁶, Lingfeng Min¹⁷, Gen Lin¹⁸, Long Huang¹⁵, Jingping Yuan¹⁹, Zhansheng Jiang²⁰, Xingxiang Pu²¹, Chuangzhou Rao²², Dongqing Lyu²³, Zongyang Yu²⁴, Xiaoyan Li²⁵, Chuanhao Tang²⁶, Chengzhi Zhou²⁷, Qi Mei¹, Hui Guo²⁸, Qian Chu²⁹, Rui Meng³⁰, Xuewen Liu³¹, Jingxun Wu³², Jin Zhou³³, Zhengfei Zhu³⁴, Weiwei Pan³⁵, Fei Pang³⁶, Meizhen Hu³⁶, Kai Wang³⁶, Fan Wu³⁷, Bingwei Xu³⁸, Ling Xu³⁹, Liping Wang⁴⁰, Youcai Zhu⁴¹, Jisheng Li⁴², Yanru Xie⁴³, Xinqing Lin²⁷, Jing Cai¹⁵, Lin Wang⁴⁴, Yingying Du⁴⁵, Wang Yao⁴⁶, Xuefei Shi⁴⁷, Xiaomin Niu⁷, Dongmei Yuan⁵, Yanwen Yao⁵, Jing Kang⁹, Jiatao Zhang⁹, Chao Zhang⁹, Wenbin Gao⁴⁸, Jianhui Huang⁴³, Yinbin Zhang⁴⁹, Pingli Sun⁵⁰, Hong Wang⁵¹, Mingxiang Ye⁵, Dong Wang⁵, Zhaofeng Wang⁵, Yue Hao³, Zheng Wang⁵², Bing Wan⁵³, Donglai Lyu⁵⁴, Xiaodong Jiao⁵⁵, Lin Shi⁵⁶, Gang Lan⁴¹, Shengjie Yang⁵⁷, Yanhong Shang⁵⁸, Yina Wang⁵⁹, Bihui Li⁶⁰, Gang Jin⁶¹, Kang Zheng⁶², Jun Ma⁶³, Wenfeng Li⁶⁴, Zhang Zhang⁶⁵, Zhongwu Li⁶⁶, Yuan Li⁶⁷, Zhefeng Liu⁵¹, Xuelei Ma⁶⁸, Nong Yang¹¹, Lin Wu²¹, Qiming Wang⁶⁹, Guansong Wang⁷⁰, Zhuan Hong⁷¹, Jiandong Wang⁷², Meiyu Fang³, Yong Fang⁷³, Xixu Zhu⁵², Yi Shen⁷⁴, Ke Wang^{75

76}, Xiubao Ren⁷⁷, Yiping Zhang³, Shenglin Ma⁷⁸, Junping Zhang^#¹, Yong Song^#⁵, Wenfeng Fang^#⁷⁹, Yuanzhi Lu^#⁸⁰

Affiliations

¹ Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China.
² Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou 310009, China.
³ Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou 310022, China.
⁴ Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
⁵ Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁶ Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China.
⁷ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
⁸ Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
⁹ Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou 510080, China.
¹⁰ State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
¹¹ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
¹² Department of Thoracic Cancer, Jilin Cancer Hospital, Changchun 130012, China.
¹³ Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China.
¹⁴ Department of VIP Inpatient, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
¹⁵ Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
¹⁶ Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China.
¹⁷ Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, China.
¹⁸ Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou 350014, China.
¹⁹ Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
²⁰ Department of Integrative Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
²¹ Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
²² Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo 315010, China.
²³ Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou 317000, China.
²⁴ Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou 350025, China.
²⁵ Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100700, China.
²⁶ Department of Medical Oncology, Peking University International Hospital, Beijing 102206, China.
²⁷ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510300, China.
²⁸ Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
²⁹ Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
³⁰ Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
³¹ Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha 410013, China.
³² Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen 361003, China.
³³ Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
³⁴ Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
³⁵ Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing 314001, China.
³⁶ Shanghai OrigiMed Co, Ltd, Shanghai 201114, China.
³⁷ Menarini Silicon Biosystems SpA, Shanghai 200333, China.
³⁸ Department of Biotherapy, Cancer Institute, First Affiliated Hospital of China Medical University, Shenyang 110001, China.
³⁹ Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei 230011, China.
⁴⁰ Department of Oncology, Baotou Cancer Hospital, Baotou 014000, China.
⁴¹ Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing 314000, China.
⁴² Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
⁴³ Department of Oncology, Lishui Municipal Central Hospital, Lishui 323000, China.
⁴⁴ Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China.
⁴⁵ Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
⁴⁶ Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, China.
⁴⁷ Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou 313000, China.
⁴⁸ Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.
⁴⁹ Department of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710004, China.
⁵⁰ Department of Pathology, The Second Hospital of Jilin University, Changchun 130041, China.
⁵¹ Senior Department of Oncology, The 5th Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
⁵² Department of Radiation Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁵³ Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China.
⁵⁴ Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei 230031, China.
⁵⁵ Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200070, China.
⁵⁶ Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
⁵⁷ Department of Thoracic Surgery, Chuxiong Yi Autonomous Prefecture People's Hospital, Chuxiong 675000, China.
⁵⁸ Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.
⁵⁹ Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
⁶⁰ Department of Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China.
⁶¹ Department of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
⁶² Department of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, China.
⁶³ Department of Thoracic Surgery, Shanxi Provincial People's Hospital/The Fifth Hospital of Shanxi Medical University/The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China.
⁶⁴ Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
⁶⁵ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou 510632, China.
⁶⁶ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
⁶⁷ Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
⁶⁸ Department of Biotherapy, State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
⁶⁹ Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
⁷⁰ Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
⁷¹ Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210029, China.
⁷² Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁷³ Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.
⁷⁴ Department of Thoracic Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁷⁵ National Health Commission (NHC) Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
⁷⁶ Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 210000, China.
⁷⁷ Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
⁷⁸ Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China.
⁷⁹ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
⁸⁰ Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.

^# Contributed equally.

PMID: 40200811
PMCID: PMC11976709
DOI: 10.20892/j.issn.2095-3941.2024.0503

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Huijing Feng et al. Cancer Biol Med. 2025.

. 2025 Apr 8;22(3):237-265.

doi: 10.20892/j.issn.2095-3941.2024.0503.

Authors

Affiliations

¹ Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China.
² Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou 310009, China.
³ Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou 310022, China.
⁴ Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
⁵ Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁶ Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China.
⁷ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
⁸ Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
⁹ Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou 510080, China.
¹⁰ State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
¹¹ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
¹² Department of Thoracic Cancer, Jilin Cancer Hospital, Changchun 130012, China.
¹³ Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China.
¹⁴ Department of VIP Inpatient, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
¹⁵ Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
¹⁶ Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China.
¹⁷ Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, China.
¹⁸ Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou 350014, China.
¹⁹ Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
²⁰ Department of Integrative Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
²¹ Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
²² Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo 315010, China.
²³ Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou 317000, China.
²⁴ Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou 350025, China.
²⁵ Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100700, China.
²⁶ Department of Medical Oncology, Peking University International Hospital, Beijing 102206, China.
²⁷ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510300, China.
²⁸ Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
²⁹ Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
³⁰ Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
³¹ Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha 410013, China.
³² Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen 361003, China.
³³ Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
³⁴ Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
³⁵ Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing 314001, China.
³⁶ Shanghai OrigiMed Co, Ltd, Shanghai 201114, China.
³⁷ Menarini Silicon Biosystems SpA, Shanghai 200333, China.
³⁸ Department of Biotherapy, Cancer Institute, First Affiliated Hospital of China Medical University, Shenyang 110001, China.
³⁹ Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei 230011, China.
⁴⁰ Department of Oncology, Baotou Cancer Hospital, Baotou 014000, China.
⁴¹ Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing 314000, China.
⁴² Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
⁴³ Department of Oncology, Lishui Municipal Central Hospital, Lishui 323000, China.
⁴⁴ Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China.
⁴⁵ Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
⁴⁶ Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, China.
⁴⁷ Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou 313000, China.
⁴⁸ Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.
⁴⁹ Department of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710004, China.
⁵⁰ Department of Pathology, The Second Hospital of Jilin University, Changchun 130041, China.
⁵¹ Senior Department of Oncology, The 5th Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
⁵² Department of Radiation Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁵³ Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China.
⁵⁴ Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei 230031, China.
⁵⁵ Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200070, China.
⁵⁶ Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
⁵⁷ Department of Thoracic Surgery, Chuxiong Yi Autonomous Prefecture People's Hospital, Chuxiong 675000, China.
⁵⁸ Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.
⁵⁹ Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
⁶⁰ Department of Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China.
⁶¹ Department of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China.
⁶² Department of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, China.
⁶³ Department of Thoracic Surgery, Shanxi Provincial People's Hospital/The Fifth Hospital of Shanxi Medical University/The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China.
⁶⁴ Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
⁶⁵ International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou 510632, China.
⁶⁶ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
⁶⁷ Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
⁶⁸ Department of Biotherapy, State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
⁶⁹ Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
⁷⁰ Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
⁷¹ Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210029, China.
⁷² Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁷³ Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.
⁷⁴ Department of Thoracic Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
⁷⁵ National Health Commission (NHC) Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
⁷⁶ Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 210000, China.
⁷⁷ Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
⁷⁸ Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China.
⁷⁹ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
⁸⁰ Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.

^# Contributed equally.

PMID: 40200811
PMCID: PMC11976709
DOI: 10.20892/j.issn.2095-3941.2024.0503

Abstract

Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include MET exon 14 skipping mutations (MET exon 14 skipping), MET gene amplifications, MET point mutations (primarily kinase domain mutations), and MET protein overexpression. Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes. The East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG, Yangtze River Delta Lung Cancer Cooperation Group) has synthesized insights from China's innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations. This consensus addresses key areas, such as optimal testing timing, testing methods, testing strategies, quality control measures, and treatment approaches. By offering standardized recommendations, this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.

Keywords: MET amplification; MET exon 14 skipping mutation; Mesenchymal-epithelial transition factor; non-small cell lung cancer; precision medicine; targeted therapy; tyrosine kinase.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

**Figure 1**
Frequency and location of *MET* hotspots in NSCLC. Schematic diagram of *MET* mutation hotspots and locations of lung cancer in Chinese population. SEMA, semaphorin; PSI, plexin-semaphorin-integrin domain; IPT, immunoglobulin-plexins-transcription domain; TK, tyrosine kinase domain.

**Figure 2**
Judgment criteria of *MET* dual probe *in situ* hybridization testing.

**Figure 3**
Strategy of MET testing in NSCLC.

See this image and copyright information in PMC

References

1. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53. - PMC - PubMed
1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. - PubMed
1. Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 2013;19:316–23. - PubMed
1. Sakai K, Aoki S, Matsumoto K. Hepatocyte growth factor and Met in drug discovery. J Biochem. 2015;157:271–84. - PubMed
1. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692–7. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53. - PMC - PubMed

[2] Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53. - PMC - PubMed

[3] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. - PubMed

[4] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. - PubMed

[5] Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 2013;19:316–23. - PubMed

[6] Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 2013;19:316–23. - PubMed

[7] Sakai K, Aoki S, Matsumoto K. Hepatocyte growth factor and Met in drug discovery. J Biochem. 2015;157:271–84. - PubMed

[8] Sakai K, Aoki S, Matsumoto K. Hepatocyte growth factor and Met in drug discovery. J Biochem. 2015;157:271–84. - PubMed

[9] Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692–7. - PMC - PubMed

[10] Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692–7. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Affiliations

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous